<html>
<head>
  <title>SARS-CoV-2 RNA-dependent RNA polymerase member protein of the core replicase complex (a.k.a. NSP12) (RdRp) gene V166L;P323L literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="RdRp.html">RNA-dependent RNA polymerase member protein of the core replicase complex (a.k.a. NSP12) (RdRp)</a> gene <span class="constellation">RdRp:p.V166L;P323L</span> literature reference collection</h1>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This mutation combination (with construct P323L on a D614G wildtype backbone),  is the only one present after 17 passages in 10uM remdesivir. V166L is outside the active polymerase site. <br/> EC50 in a plaque reduction assay was 2.3x in the passage experiment, but only 1.5x when introduced on a WA1 backbone and measured using a luciferase assay.<br/> (<a href="https://doi.org/10.1101/2022.02.07.479493" class="lit_link">Checkmahomed et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
